UK medicines regulator approves new weight loss pill

Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleThe UK's MHRA has become the first regulator in Europe to authorise orforglipron, known as Foundayo, a daily pill for weight loss and type 2 diabetes. Manufactured by Eli Lilly, the GLP-1 receptor agonist medication works by lowering blood sugar levels, slowing digestion, and reducing appetite. The prescription-only tablet is licensed for adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition. Taken once a day without food or water restrictions, the treatment involves a monthly step-up in dosage levels. Although authorised in the UK, Foundayo is not yet available on the NHS and must first be evaluated by health watchdog NICE. In fullNew once-daily weight loss pill approved by the UK medicines regulatorMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in

Raccontata dadailymail.compolitiken.dkindependent.co.ukvalor.globo.comclarin.comeconomictimes.indiatimes.comhotnews.rocnbc.comlemonde.frqz.comg4media.ro